Related Experiment Videos
Intralesional alfa-2a interferon therapy for basal cell carcinoma
B Doğan1, Y Harmanyeri, H Baloğlu
1GATA Haydarpaşa Teaching Hospital, Department of Dermatology, Istanbul, Turkey.
Cancer Letters
|May 8, 1995
Summary
Intralesional interferon alfa-2a effectively treats basal cell carcinoma (BCC), a common skin cancer. Most patients achieved complete cure within 36 weeks, showing it
Area of Science:
- Dermatology
- Oncology
- Medical Research
Background:
- Basal cell carcinoma (BCC) is a prevalent epithelial skin tumor originating from epidermal basal cells.
- Current therapeutic options for BCC include surgical and non-surgical modalities.
Purpose of the Study:
- To evaluate the efficacy of intralesional interferon alfa-2a as a treatment for histopathologically-proven basal cell carcinoma.
- To determine if intralesional interferon therapy is a viable alternative to surgical interventions for BCC.
Main Methods:
- Thirteen patients with facial or truncal BCC underwent treatment with intralesional interferon alfa-2a.
- Treatment involved a sufficient dose and duration tailored to individual cases.
Main Results:
- Complete cure was observed in 11 out of 13 patients within 12 to 36 weeks.
- Only 2 patients required subsequent surgical intervention due to inadequate response.
Conclusions:
- Intralesional interferon alfa-2a demonstrates significant efficacy in treating noduloulcerative and superficial basal cell carcinoma.
- This therapeutic approach offers a promising, less invasive alternative to surgery for BCC management.